Production Method 1

53101-04-5

89250-26-0

Reaction Conditions

1.1 Reagents: Sodium borohydride Solvents: Ethanol ;  30 min, rt
1.2 Reagents: Thionyl chloride Catalysts: Dimethylformamide ;  1 h, reflux

Reference

Design, synthesis, and biological evaluation of N,N-disubstituted-4-arylthiazole-2-methylamine derivatives as cholesteryl ester transfer inhibitors

Wang, Xinran; Lin, Xuehua; Xu, Xuanqi; Li, Wei; Hao, Lijuan; et al, Molecules, 2017, 22(11), 1925/1-1925/16

Astragalus Polysacharin Raw materials

• Ethyl 4-(4-nitrophenyl)-1,3-thiazole-2-carboxylate

Astragalus Polysacharin Preparation Products

• Astragalus Polysacharin (89250-26-0)

• 1. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 2. Achieving high-efficiency purely organic room-temperature phosphorescence materials by boronic ester substitution of phenoxathiine?
  Mengke Li,Xinyi Cai,Zhenyang Qiao,Wentao Xie,Liangying Wang,Nan Zheng,Shi-Jian Su Chem. Commun., 2019,55, 7215-7218
• 3. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Nitrobenzenes
• Other Chemical Reagents

Introduction to Astragalus Polysaccharin (CAS No. 89250-26-0) and Its Recent Research Findings

Astragalus Polysaccharin, a bioactive compound with the chemical identifier CAS No. 89250-26-0, has garnered significant attention in the field of pharmaceuticals and nutraceuticals due to its remarkable biological properties. This polysaccharide, derived from the roots of Astragalus membranaceus, a plant widely used in traditional Chinese medicine, has been the subject of extensive research over the past few decades. Its multifaceted therapeutic potential, ranging from immunomodulation to anti-inflammatory effects, has positioned it as a promising candidate for various clinical applications.

The structure of Astragalus Polysaccharin is characterized by its complex composition, which includes glucose, rhamnose, and galactose units arranged in a highly branched manner. This structural complexity contributes to its unique biological activity and interaction with various cellular pathways. Recent studies have highlighted the role of Astragalus Polysaccharin in enhancing the body's defense mechanisms, particularly in modulating the immune system. This has been demonstrated through its ability to activate macrophages and enhance the production of cytokines such as interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-α).

One of the most compelling areas of research involving Astragalus Polysaccharin is its potential in cancer therapy. Preclinical studies have shown that it can inhibit tumor growth and metastasis by inducing apoptosis in cancer cells while simultaneously enhancing the efficacy of conventional chemotherapeutic agents. The mechanism behind this effect involves the modulation of signaling pathways such as Akt, NF-κB, and MAPK, which are crucial for cell survival and proliferation. Additionally, Astragalus Polysaccharin has been found to possess antioxidant properties, helping to mitigate oxidative stress—a key factor in cancer progression.

In recent years, there has been growing interest in using Astragalus Polysaccharin as a complementary therapy for chronic inflammatory diseases. Chronic inflammation is associated with a range of conditions, including rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis. Studies have demonstrated that Astragalus Polysaccharin can reduce inflammation by inhibiting the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and interleukin-1β (IL-1β). Furthermore, it has been shown to suppress the activity of nuclear factor kappa B (NF-κB), a transcription factor that regulates inflammatory responses.

The cardiovascular system has also been a focus of research regarding Astragalus Polysaccharin. Evidence suggests that it can improve endothelial function by promoting the production of nitric oxide (NO), a vasodilator molecule that helps maintain healthy blood pressure levels. Additionally, it has been shown to reduce oxidative stress and inhibit platelet aggregation, thereby lowering the risk of thrombosis and atherosclerosis. These findings make Astragalus Polysaccharin a promising candidate for preventing and managing cardiovascular diseases.

Another area where Astragalus Polysaccharin has shown promise is in neuroprotection. Oxidative stress and inflammation are key factors in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Research indicates that Astragalus Polysaccharin can cross the blood-brain barrier and protect neurons from damage by reducing oxidative stress and inhibiting inflammatory responses. Furthermore, it has been found to enhance cognitive function by improving synaptic plasticity and memory retention.

The antimicrobial properties of Astragalus Polysaccharin have also been explored in recent studies. It has been shown to exhibit activity against a range of bacteria, fungi, and viruses by disrupting their cell membranes and inhibiting their growth. This makes it a potential candidate for developing novel antimicrobial agents that could combat drug-resistant infections.

Given its diverse range of biological activities, Astragalus Polysaccharin is being evaluated in clinical trials for various health conditions. These trials aim to validate the safety and efficacy of this compound in human populations and to identify optimal dosing regimens. The results so far have been encouraging, with preliminary data suggesting that Astragalus Polysaccharin can be safely administered at doses comparable to those used in traditional medicine.

The future prospects for Astragalus Polysaccharin are bright, with ongoing research focusing on elucidating its mechanisms of action and exploring new therapeutic applications. Advances in biotechnology have enabled more efficient extraction and purification methods for this compound, making it more accessible for clinical use. Additionally, novel delivery systems are being developed to enhance its bioavailability and therapeutic efficacy.

In conclusion, Astragalus Polysaccharin (CAS No. 89250-26-0) is a bioactive polysaccharide with significant therapeutic potential across multiple domains of medicine. Its ability to modulate immune responses, reduce inflammation, protect against oxidative stress, and enhance cellular function makes it a promising candidate for treating various chronic diseases. As research continues to uncover new insights into its mechanisms of action, Astragalus Polysaccharin is poised to become an important therapeutic agent in modern medicine.

• 5286-89-5(Thiazole, 2,2'-(1,3-phenylene)bis[4-(4-nitrophenyl)-)
• 2521-25-7(Thiazole, 4-(4-nitrophenyl)-2-phenyl-)
• 302918-03-2(2-Thiazoleacetonitrile, 4-(3-nitrophenyl)-)
• 3704-42-5(4-(4-Nitrophenyl)thiazole)
• 305811-37-4(2-Methyl-4-(2-nitrophenyl)thiazole)
• 33102-81-7(2-Methyl-4-(4-nitrophenyl)-1,3-thiazole)
• 657401-15-5(Benzenamine, N,N-dimethyl-4-[4-(4-nitrophenyl)-2-thiazolyl]-)
• 657401-16-6(Benzenamine, N,N-dimethyl-4-[2-(4-nitrophenyl)-4-thiazolyl]-)
• 5680-19-3(4,4'-bis(3-nitrophenyl)-2,2'-bi-1,3-thiazole)
• 69625-13-4(2-Thiazoleacetonitrile,4-(4-nitrophenyl)-)